Company profile: Scioto Biosciences
1.1 - Company Overview
Company description
- Provider of Activated Bacterial Therapeutics, including SB-121, a formulation of L. reuteri with Sephadex and maltose designed to deliver activated probiotic bacteria to the gastrointestinal tract for treating autism spectrum disorder and potentially other GI disorders, and an ABT platform that enhances delivery and efficacy of live bacterial therapeutics for GI health and diseases affecting the gut-brain axis.
Products and services
- Activated Bacterial Therapeutics (ABT) Platform: A live-bacteria-focused technology that enhances delivery and efficacy of bacterial therapeutics across gastrointestinal health and diseases affecting the gut-brain axis, enabling activated probiotic performance
- SB-121: A Sephadex-supported formulation of L. reuteri with maltose that delivers activated probiotic bacteria to the gastrointestinal tract for treating autism spectrum disorder and potentially other GI disorders
- ABT Platform Development: Scioto architects an activated-bacteria-centric platform to enhance delivery and efficacy of live bacterial therapeutics addressing gastrointestinal health and diseases affecting the gut-brain axis
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Scioto Biosciences
Kendall Research Systems
HQ: United States
Website
- Description: Provider of pioneering novel tools for neuroscience discovery using optogenetic techniques, operating as an R&D think tank developing technologies in bioinstrumentation, ultra-low power computation, and communications links; originated in 2011 as an optical neural interface technology spin-out from MIT's Synthetic Neurobiology Lab.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kendall Research Systems company profile →
Teneobio
HQ: United States
Website
- Description: Provider of human heavy chain antibody discovery and development, with pre-clinical and clinical programs for multiple myeloma, prostate cancer, and immune disorders. Its antibody discovery engine is based on UniRat™.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Teneobio company profile →
Atomic Alchemy
HQ: United States
Website
- Description: Provider of radioisotopes for medical, research, exploration, and industrial use, aiming to establish a reliable domestic supply in the U.S. for medical radioisotopes such as molybdenum-99, in a market that currently lacks a dedicated domestic supplier and relies on university research reactors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Atomic Alchemy company profile →
PowderMed
HQ: United Kingdom
Website
- Description: Provider of Particle Mediated Epidermal Delivery (PMED) technology and vaccines for chronic infectious diseases and cancer, using DNA-coated gold particles delivered by a needle-free injection device to stimulate specific T cell immune responses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PowderMed company profile →
ProteinSimple
HQ: United States
Website
- Description: Provider of protein tools and analysis solutions that help researchers resolve protein analysis problems to reveal insights into proteins and their role in disease; part of the Protein Platforms division of Bio-Techne (NASDAQ: TECH).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ProteinSimple company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Scioto Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Scioto Biosciences
2.2 - Growth funds investing in similar companies to Scioto Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Scioto Biosciences
4.2 - Public trading comparable groups for Scioto Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →